亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

GeneRegs: Nanoparticles for Treatment of Severe Asthma

标题
Inhaled DNAzyme-Nanoparticle Conjugates to Treat Chronic Inflammation in the Lung
详细技术说明
ApplicationGold nanoparticles coated with enzyme which specifically targets and degrades asthma-associated inflammation molecules.Key BenefitsSpecifically suppresses asthma associated inflammation.Easy self-administration by inhalation.Market SummaryAsthma is defined as a chronic inflammatory lung disease with significant worldwide morbidity. Currently, inhaled corticosteroids are one of the essential long-term maintenance therapies for all patients with persistent asthma. In general, oral corticosteroids suppress the immune response to control asthma symptoms and asthma exacerbations, but the immune suppression is global rather than specifically targeted to asthma-driven inflammation or directly to the lung. Corticosteroids can also cause significant side effects, such as hyperglycemia, osteoporosis and weight gain, which require additional therapeutics to treat them. Therefore, there is a dire need for safer therapeutics treating chronic inflammatory diseases such as asthma in a specific manner without inducing side effects.Technical SummaryEmory inventors have created GeneRegs—gold nanoparticles coated with enzyme capable of specifically targeting and degrading key molecules underlying pathogenesis in asthma. GeneRegs can be administered in the form of micro droplets via nebulizer, which can turn liquid medicine into mist for easy inhalation. Preliminary experiments indicated that nanoparticles coated with DNAzyme specifically targeting GATA-3, a protein involved in asthma associated inflammation, can provide effective treatment in mice models of asthma. This nucleobase polymer degrades GATA-3 mRNA, enabling the management of disorders associated with excessive GATA-3 expression. GeneRegs may provide more efficient and safer inflammatory and respiratory therapeutics that can substitute corticosteroid use in severe asthma and other chronic inflammations.Developmental StageProof of concept has been demonstrated in animal model.
*Abstract
None
*Principal Investigation

Name: Khalid Salaita, Associate Professor

Department: ECAS: Chemistry


Name: Cherry Wongtrakool, Assistant Professor

Department: SOM: Medicine: Pulmonology


Name: Kornelia Galior, Post Doctoral Fellow

Department: Chemistry

申请日期
May 24, 2017
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备